Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 256Terminated 99Unknown 62Recruiting 46Active not recruiting 27Withdrawn 24Not yet recruiting 10No longer available 3Suspended 2Enrolling by invitation 2Available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 33Neoplasms 28Colorectal Neoplasms 19Prostatic Neoplasms 17Lung Neoplasms 13Leukemia, Myeloid, Acute 12Glioblastoma 12Stomach Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Glioma 8Brain Neoplasms 8Rectal Neoplasms 7Ovarian Neoplasms 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Hematologic Neoplasms 6Uterine Cervical Neoplasms 5Polycystic Ovary Syndrome 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Sarcoma 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Lymphoma 4

Interventions

vactosertib 1fludarabine phosphate 1aldesleukin 1Interleukin-2 1IL32 protein, human 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Case Comprehensive Cancer Center

Phase 1 Suspended
12 enrolled
GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01755325 2018-04-25

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Ruijin Hospital

Phase 3 Suspended
680 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡